The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of nimotuzumab combination with paclitaxel and cisplatin as the first-line treatment in patients with local advanced or metastatic esophageal squamous cell cancer (ESCC): An interim analysis.
Xiaodong Zhang
No relevant relationships to disclose
Ming Lu
No relevant relationships to disclose
Jifang Gong
No relevant relationships to disclose
Jing Gao
No relevant relationships to disclose
Xicheng Wang
No relevant relationships to disclose
Xiaotian Zhang
No relevant relationships to disclose
Jie Li
No relevant relationships to disclose
Yan Li
No relevant relationships to disclose
Jian Li
No relevant relationships to disclose
Jun Zhou
No relevant relationships to disclose
Zhihao Lu
No relevant relationships to disclose
Lin Shen
No relevant relationships to disclose